Excel CSV XML Print

₅Gary T Kinasewitz

Key Opinion Leader In [Gary T Kinasewitz is considered a key opinion leader in any keyword where the rank of 5 is achieved, the leading number before the keyword shows the author's rank as compared to all other authors]

₂₃Protein C | ₆₂Sepsis | ₁₇₁Inflammation | ₅₄₉Recombinant Proteins

Keywords (32) [keywords assigned to Gary T Kinasewitz articles by PubMed, the leading number and the color conveys importance]

₅Humans | ₃Recombinant Proteins | ₃Sepsis | ₃Protein C | ₃Inflammation | ₂Survival Analysis | ₂Blood Coagulation | ₂Biological Markers | ₂Dose-Response Relationship, Drug | ₂Anti-Infective Agents | ₂Double-Blind Method | ₁Confidence Intervals | ₁Follow-Up Studies | ₁Fungi | ₁Paracentesis | ₁Thoracoscopy | ₁Gram-Positive Bacterial Infections | ₁Lipopolysaccharides | ₁Drug Administration Schedule | ₁Escherichia coli | ₁Gram-Negative Bacterial Infections | ₁Plasminogen Activator Inhibitor 1 | ₁APACHE | ₁Intensive Care Units | ₁Severity of Illness Index | ₁Animals | ₁Anti-Bacterial Agents | ₁Neprilysin | ₁Stem Cells | ₁Radionuclide Imaging | ₁Papio | ₁Time Factors

Other [context-specific ads]

Gary T Kinasewitz Unique Vocabulary (96) [single words, word pairs and phrases obtained by analysis of abstracts and titles, the leading number and the color conveys importance; Gary T Kinasewitz might be a good expert witness on these terms]

₁₉activated | ₁₈patients | ₁₇drotrecogin | ₁₇alfa | ₁₄sepsis | ₁₃severe | ₁₁cd10 | ₈expression | ₈reduced | ₇results | ₇neutrophil | ₇prowess | ₆response | ₆observed | ₆pleural | ₆treatment | ₅hydrothorax | ₅significant | ₅human | ₅challenge | ₄underlying | ₄inflammatory | ₄effect | ₄can | ₄therapy | ₄data | ₄levels | ₄fluid | ₄placebo | ₃confidence | ₃interval | ₃patient
₁₇drotrecogin alfa | ₁₇alfa activated | ₁₃severe sepsis | ₈patients severe | ₆cd10 expression | ₅neutrophil cd10 | ₅effects drotrecogin | ₄hepatic hydrothorax | ₄evaluation committee | ₄clinical evaluation | ₄prowess trial | ₃significant underlying | ₃confidence interval | ₃sepsis prowess | ₃change baseline | ₃systemic biomarkers | ₂reduces host | ₂recombinant human | ₂activated protein | ₂human activated | ₂review data | ₂effect significant | ₂neutrophil surface | ₂imputation method | ₂reduced neutrophil | ₂underlying disorders | ₂inflammatory challenge | ₂centers enrolled | ₂preinjection levels | ₂baseline analyses | ₂expression nonhuman | ₂resolved preinjection
₁₇drotrecogin alfa activated | ₈patients severe sepsis | ₅neutrophil cd10 expression | ₅effects drotrecogin alfa | ₄clinical evaluation committee | ₃severe sepsis prowess | ₂patients medical centers | ₂nonhuman primates humans | ₂severe sepsis patients | ₂primates humans vivo | ₂integrated review data | ₂coagulopathy response patients | ₂reduces host coagulopathy | ₂protein reduces host | ₂medical centers enrolled | ₂expression nonhuman primates | ₂humans vivo challenge | ₂effect significant locf | ₂confidence interval 69-0 | ₂activated recombinant human | ₂blinded critical integrated | ₂benefit associated drotrecogin | ₂response patients severe | ₂resolved preinjection levels | ₂recombinant human activated | ₂centers enrolled prowess | ₂significant underlying disorders | ₂percent change baseline | ₂significant locf imputation | ₂activated protein reduces | ₂reduced neutrophil cd10 | ₂alfa activated recombinant

Authoratory™
•home •community •tutorial •authors •keywords •search •top ranked •NEH grants •login	Excel CSV XML Print ₅Gary T Kinasewitz 2002 \| 2003 \| 2004 >> Summary Social Network Interests Funding Articles Comments All Key Opinion Leader In [Gary T Kinasewitz is considered a key opinion leader in any keyword where the rank of 5 is achieved, the leading number before the keyword shows the author's rank as compared to all other authors] ₂₃Protein C \| ₆₂Sepsis \| ₁₇₁Inflammation \| ₅₄₉Recombinant Proteins Keywords (32) [keywords assigned to Gary T Kinasewitz articles by PubMed, the leading number and the color conveys importance] ₅Humans \| ₃Recombinant Proteins \| ₃Sepsis \| ₃Protein C \| ₃Inflammation \| ₂Survival Analysis \| ₂Blood Coagulation \| ₂Biological Markers \| ₂Dose-Response Relationship, Drug \| ₂Anti-Infective Agents \| ₂Double-Blind Method \| ₁Confidence Intervals \| ₁Follow-Up Studies \| ₁Fungi \| ₁Paracentesis \| ₁Thoracoscopy \| ₁Gram-Positive Bacterial Infections \| ₁Lipopolysaccharides \| ₁Drug Administration Schedule \| ₁Escherichia coli \| ₁Gram-Negative Bacterial Infections \| ₁Plasminogen Activator Inhibitor 1 \| ₁APACHE \| ₁Intensive Care Units \| ₁Severity of Illness Index \| ₁Animals \| ₁Anti-Bacterial Agents \| ₁Neprilysin \| ₁Stem Cells \| ₁Radionuclide Imaging \| ₁Papio \| ₁Time Factors Other [context-specific ads] Gary T Kinasewitz Unique Vocabulary (96) [single words, word pairs and phrases obtained by analysis of abstracts and titles, the leading number and the color conveys importance; Gary T Kinasewitz might be a good expert witness on these terms] ₁₉activated \| ₁₈patients \| ₁₇drotrecogin \| ₁₇alfa \| ₁₄sepsis \| ₁₃severe \| ₁₁cd10 \| ₈expression \| ₈reduced \| ₇results \| ₇neutrophil \| ₇prowess \| ₆response \| ₆observed \| ₆pleural \| ₆treatment \| ₅hydrothorax \| ₅significant \| ₅human \| ₅challenge \| ₄underlying \| ₄inflammatory \| ₄effect \| ₄can \| ₄therapy \| ₄data \| ₄levels \| ₄fluid \| ₄placebo \| ₃confidence \| ₃interval \| ₃patient ₁₇drotrecogin alfa \| ₁₇alfa activated \| ₁₃severe sepsis \| ₈patients severe \| ₆cd10 expression \| ₅neutrophil cd10 \| ₅effects drotrecogin \| ₄hepatic hydrothorax \| ₄evaluation committee \| ₄clinical evaluation \| ₄prowess trial \| ₃significant underlying \| ₃confidence interval \| ₃sepsis prowess \| ₃change baseline \| ₃systemic biomarkers \| ₂reduces host \| ₂recombinant human \| ₂activated protein \| ₂human activated \| ₂review data \| ₂effect significant \| ₂neutrophil surface \| ₂imputation method \| ₂reduced neutrophil \| ₂underlying disorders \| ₂inflammatory challenge \| ₂centers enrolled \| ₂preinjection levels \| ₂baseline analyses \| ₂expression nonhuman \| ₂resolved preinjection ₁₇drotrecogin alfa activated \| ₈patients severe sepsis \| ₅neutrophil cd10 expression \| ₅effects drotrecogin alfa \| ₄clinical evaluation committee \| ₃severe sepsis prowess \| ₂patients medical centers \| ₂nonhuman primates humans \| ₂severe sepsis patients \| ₂primates humans vivo \| ₂integrated review data \| ₂coagulopathy response patients \| ₂reduces host coagulopathy \| ₂protein reduces host \| ₂medical centers enrolled \| ₂expression nonhuman primates \| ₂humans vivo challenge \| ₂effect significant locf \| ₂confidence interval 69-0 \| ₂activated recombinant human \| ₂blinded critical integrated \| ₂benefit associated drotrecogin \| ₂response patients severe \| ₂resolved preinjection levels \| ₂recombinant human activated \| ₂centers enrolled prowess \| ₂significant underlying disorders \| ₂percent change baseline \| ₂significant locf imputation \| ₂activated protein reduces \| ₂reduced neutrophil cd10 \| ₂alfa activated recombinant Science Trivia (2) [Interactive math & science trivia questions]

	The content of this page was generated automatically by a computer program. Copyright © 2006-2010 Authoratory.com \| All rights reserved \| Terms of use \| Privacy policy

5Gary T Kinasewitz

Key Opinion Leader In [Gary T Kinasewitz is considered a key opinion leader in any keyword where the rank of 5 is achieved, the leading number before the keyword shows the author's rank as compared to all other authors]

Keywords (32) [keywords assigned to Gary T Kinasewitz articles by PubMed, the leading number and the color conveys importance]

Other [context-specific ads]

Gary T Kinasewitz Unique Vocabulary (96) [single words, word pairs and phrases obtained by analysis of abstracts and titles, the leading number and the color conveys importance; Gary T Kinasewitz might be a good expert witness on these terms]

Science Trivia (2) [Interactive math & science trivia questions]

₅Gary T Kinasewitz